Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1- CRAD001CUS232T

NCT02332902 is registered in ClinicalTrials.gov with The University of Texas Health Science Center, Houston as lead sponsor.

NCT NCT02332902
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02332902 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1- CRAD001CUS232T
Lead sponsor
The University of Texas Health Science Center, Houston
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2015
Completion date
March 31, 2016
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neurofibromatosis 1